ACE Technology Guidances communicate recommendations from the MOH Drug Advisory Committee or the MOH Medical Technology Advisory Committee on the funding status and appropriate use of drugs, vaccines or medical technologies that have been evaluated by ACE. The guidances also include the Committee’s rationale for the funding recommendations, and key clinical and economic evidence which informed their deliberations. Plain English Summaries (PES) to explain ACE Technology Guidances are available for patients and the public.

Published on 04 Jan 2022
Last Updated on 19 Dec 2022
A- A+
Guidance Recommendations
The Ministry of Health’s Drug Advisory Committee has recommended:
  • Degarelix 80 mg and 120 mg injections;
  • Enzalutamide 40 mg capsule; and
  • Olaparib 100 mg and 150 mg tablets
for treating prostate cancer in line with specific clinical criteria.

Subsidy status

Degarelix 80 mg and 120 mg injections are recommended for inclusion on the Medication Assistance Fund (MAF) for treating advanced hormone-dependent prostate cancer with effect from 4 January 2022.

Enzalutamide 40 mg capsule, in combination with androgen deprivation therapy (ADT) is recommended for inclusion on MAF with effect from 1 September 2022 for treating:
  • high-risk non-metastatic castration-resistant prostate cancer (nmCRPC);
  • metastatic hormone-sensitive prostate cancer (mHSPC); and
  • metastatic castration-resistant prostate cancer (mCRPC).
Olaparib 100 mg and 150 mg tablets are recommended for inclusion on MAF with effect from 1 September 2022, for treating patients with metastatic castration-resistant prostate cancer and homologous recombination repair gene BRCA1/2 and/or ATM-mutations (germline and/or somatic) whose disease has progressed following prior treatment with abiraterone or a second-generation anti-androgen. Androgen deprivation therapy (ADT) should be continued.

MAF assistance does not apply to apalutamide 60 mg tablet, darolutamide 300 mg tablet, olaparib 50 mg capsule or cabazitaxel 60 mg/1.5 mL injection for the treatment of prostate cancer.

Clinical indications, subsidy class and MediShield Life claim limits for all drugs included in the evaluation are provided in the Annex.

Review of cancer drugs for prostate cancer (Updated 19 December 2022) PES Treatments for advanced prostate cancer (Updated 19 Dec 2022)